Publications
109
Citations
1,485
Est. group size
~42
Recurring co-author estimate
Active years
59
Publishing since 1968
Walter Hanel's work focuses on lymphomas and related blood cancers, including Hodgkin lymphoma, non-Hodgkin lymphoma, mantle cell lymphoma, and rare T-cell lymphomas. His research includes clinical trials of new drug combinations, analyses of treatment outcomes and prognosis, and reviews summarizing evolving treatment options for these cancers. Much of the work is clinically oriented, drawing on patient outcome data and multi-center studies to inform how these blood cancers are managed.
Publication output has grown substantially over the last decade, rising from just 1 paper in 2017 to over a dozen per year since 2022, with a notable peak in 2025.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Phase I/II Study of Subasumstat (TAK-981) in Combination With Rituximab in Relapsed/Refractory Non-Hodgkin Lymphoma
Clinical Lymphoma Myeloma & Leukemia · 2025
- Hepatosplenic T-Cell Lymphoma
2025
- Evaluation of prognostic factors in patients with high-risk classical Hodgkin lymphoma undergoing autologous transplantation
Blood Advances · 2024
- Correction to: Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis
Cell Death and Differentiation · 2024
- Another step toward frontline BTK inhibitor therapy in MCL
Blood Advances · 2023
- Management of classical Hodgkin lymphoma: a look at up to date evidence and current treatment approaches
Experimental Hematology and Oncology · 2022
- Cytokines, Interferons, and Hematopoietic Growth Factors
Holland‐Frei Cancer Medicine · 2022
- Evolving therapeutic landscape in follicular lymphoma: a look at emerging and investigational therapies
Journal of Hematology & Oncology · 2021
- Impact of initial chemotherapy regimen on outcomes for patients with double‐expressor lymphoma: A multi‐center analysis
Hematological Oncology · 2021
- Post‐relapse survival in Waldenstrom macroglobulinemia patients experiencing therapy failure following autologous transplantation
Hematological Oncology · 2021
- Author response for "Impact of initial chemotherapy regimen on outcomes for patients with double-expressor lymphoma: A multi-center analysis"
2021
- Author response for "Post‐relapse survival in Waldenstrom macroglobulinemia patients experiencing therapy failure following autologous transplantation"
2021
- Emerging therapies in mantle cell lymphoma
Journal of Hematology & Oncology · 2020
- Hepatosplenic T-Cell Lymphoma
2020
- Impact of Novel Agents on Outcomes of Patients with Classical Hodgkin Lymphoma and Primary Treatment Failure
Blood · 2019
- Blood×22
- Blood Advances×6
- Transplantation and Cellular Therapy×5
- Journal of Hematology & Oncology×4
- Hematological Oncology×4
- Jonathan E. Brammer
Medicine · The Ohio State University
- Zachary Braunstein
Medicine · The Ohio State University
- Narendranath Epperla
Medicine · The Ohio State University
- Kaitlin Annunzio
Medicine · The Ohio State University
- Timothy Voorhees
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile